Clinico-epidemiological nature and antibiotic susceptibility profile of Acinetobacter species

Pakistan Journal of Medical Sciences

Volumn 29, Issue 2, 2013, Pages

  Biglari, Shirin ^a   Hanafiah, Alfizah ^a   Ramli, Ramliza ^a   Rahman, Md Mostafizur ^a   Nizam Khaithir, Tzar Mohd ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

Author keywords

Acinetobacter spp.; Antimicrobial susceptibility; Intensive care unit; Polymyxin B

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; SULPERAZON; SULTAMICILLIN; TIGECYCLINE;

ACINETOBACTER; ACINETOBACTER INFECTION; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CLINICAL FEATURE; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISK DIFFUSION; FEMALE; HOSPITAL INFECTION; HUMAN; HUMAN TISSUE; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NONHUMAN; OBSERVATIONAL STUDY; RESPIRATORY SYSTEM; RETROSPECTIVE STUDY; SOFT TISSUE INJURY; SURGICAL WARD; TERTIARY HEALTH CARE;

EID: 84875119342     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008;46(8):1254-1263.
2. Kong BH, Hanifah YA, Mohd Yusof MY, Thong KL. Antimicrobial Susceptibility Profiling and Genomic Diversity of Multidrug-Resistant Acinetobacter baumannii Isolates from a Teaching Hospital in Malaysia. Jpn J Infect Dis. 2011;64(4):337-340.
3. Deris ZZ, Harun A, Oman M, Johari MR. The prevalence and risk factors of nosocomial Acinetobacter blood stream infections in tertiary teaching hospital in north-eastern Malaysia. J Tropical Biomedicine. 2009;26(2):123-129.
4. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility testing. 17th informational supplement. CLSI document M100-S17. Clinical and Laboratory Standards Institute, Wayna, Pa 2009.
5. Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med. 2008;358(12):1271-1281.
6. Falagas ME, Mourtzoukou EG, Polemis M, Vatopoulos AC. Trends in antimicrobial resistance of Acinetobacter baumannii clinical isolates from hospitalized patients in Greece and treatment implications. Clin Microbiol Infect. 2007;13(8):816-819.
7. Carlet J, Fabry J, Amalberti R, Degos L. The "zero risk" concept for hospital-acquired infections: a risky business! Clin Infect Dis. 2009;49:747-749.
8. Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med. 2010;362(19):1804-1813.
9. Queenan AM, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, et al. Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010. Diagn Microbiol Infect Dis. 2012;73(3):267-270.
10. Giske CG, Monnet DL, Cars O, Carmeli Y. On behalf of ReAct-Action on Antibiotic Resistance. Clinical and economic impact of common multidrug-resistant Gram negative bacilli. J. Antimicrob Agents Chemother. 2008;52:813-821.
11. Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents. 2012;39:105-114.
12. Chang HL, Tang CH, Hsu YM, Wan L, Chang YF. Nosocomial outbreak of infection with multidrug-resistant Acinetobacter baumannii in a medical center in Taiwan. Infect. Control Hosp Epidemiol. 2009;30(1):34-38.
13. Enoch DA, Summers C, Brown NM, Moore L, Gillham MI. Investigation and management of an outbreak of multidrug carbapenem-resistant Acinetobacter baumannii in Cambridge, UK. J Hosp Infect. 2008;70(2):109-118.
14. Wendt C, Dietze B, Dietz E, Ruden H. Survival of Acinetobacter baumannii on dry surfaces. J Clin Microbiol. 1997;35(6):1394-1397.
15. Petersen K, Cannegieter SC, van der Reijden TJ, van Strijen B, You DM, Babel BS, et al. Diversity and clinical impact of Aci¬netobacter baumannii colonization and infection at a military medical center. J Clin Microbiol. 2011;49(1):159-166.
16. Smolyakov R, Borer A, Riesenberg K, Schlaeffer F, Alkan M, Porath A, et al. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. J Hosp Infect. 2003;54(1):32-38.
17. Lee SO, Kim NJ, Choi SH, Hyong Kim T, Chung JW. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: A case-control study. Antimicrobial Agents and Chemotherapy. 2004;48(1):224-228.
18. Cisneros JM, Rodriguez-Bano J, Fernandez-Cuenca F, Ribera A, Vila J, Pascual A, et al. Risk-factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain: a nationwide study. Clin Microbiol Infect. 2005;11(11):874-879.
19. Baran G, Erbay A, Bodur H, Onguru P. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. Int J Infect Dis. 2008;12(1):16-21.
20. Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977-2000. Infect Control Hosp Epidemiol. 2003; 24(4):284-295.
21. Ko KS, Suh JY, Kwon KT, Jung SI, Park KH. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother. 2007;60(5):1163-1167.
22. Tognim MC, Andrade SS, Silbert S, Gales AC, Jones RN, Sader HS. Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY Antimicrobial Surveillance Program. Int J Infect Dis. 2004;8(5):284-291.
23. NavonVenezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2007;59(4):772-774.